Progress towards effective vaccines for Chlamydia trachomatis
- 20 November 2024
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Infectious Diseases
- Vol. 38 (1) , 54-59
Abstract
Purpose of review: Effective vaccines to prevent sexually transmitted Chlamydia trachomatis (Ct) infection have eluded researchers for decades. However, recent studies of a promising vaccine in human trials, and emerging understanding of the complexity of the natural immune response to infection have provided hope for the eventual approval of a vaccine. This review highlights recent progress toward developing effective vaccines for Ct. Recent findings: In 2019, the first-in-human Ct vaccine, CTH522, Phase I/IIB trial was reported. Recent studies of this vaccine and its derivatives have further established CTH522 as the lead vaccine against sexually transmitted Ct. A variety of vaccines have entered the preclinical development pipeline, with researchers reporting efforts to target non-MOMP antigens, include novel adjuvants in vaccine formulations, and use alternative routes of administration to increase efficacy. Summary: While the approval of a vaccine for Ct is closer than ever, the need for careful consideration of future implementation is especially important for the successful clinical translation of Ct vaccines into humans.Keywords
This publication has 36 references indexed in Scilit:
- Human antibody signatures towards the Chlamydia trachomatis major outer membrane protein after natural infection and vaccinationEBioMedicine, 2024
- A novel chimeric recombinant FliC-Pgp3 vaccine promotes immunoprotection against Chlamydia muridarum infection in miceInternational Journal of Biological Macromolecules, 2023
- The Future of Sexually Transmitted Infection Research: Understanding Adolescent Perspectives for Implementation of a Chlamydia VaccineJournal of Adolescent Health, 2023
- Novel use of graphene oxide quantum dots in a pickering emulsion as a Chlamydia trachomatis vaccine adjuvantInternational Immunopharmacology, 2023
- National Institute of Allergy and Infectious Diseases workshop report: “Chlamydia vaccines: The way forward”Vaccine, 2019
- Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trialThe Lancet Infectious Diseases, 2019
- The global roadmap for advancing development of vaccines against sexually transmitted infections: Update and next stepsVaccine, 2016
- Evaluation of a multisubunit recombinant polymorphic membrane protein and major outer membrane protein T cell vaccine against Chlamydia muridarum genital infection in three strains of miceVaccine, 2014
- Towards a safe and effective chlamydial vaccine: Lessons from the eyeVaccine, 2014
- Chlamydial protease-like activity factor—insights into immunity and vaccine developmentJournal of Reproductive Immunology, 2009